Medicine | Oncology
Prostate cancer
Prognosis
Predictions for patients with metastatic hormone-sensitive prostate cancer

Home > Disciplines > Medicine > Oncology > Prostate cancer > Prognosis > Predictions for patients with mHSPC

ABIRATERONE ACETATE PLUS PREDNISONE

.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN.
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Lancet Oncol. 2019 May;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8. Epub 2019 Apr 12.
Source | Full text | Similar articles

BONE SCAN INDEX

.

Poulsen MH, Rasmussen J, Edenbrandt L, Høilund-Carlsen PF, Gerke O, Johansen A, Lund L.
Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
BJU Int. 2016 May;117(5):748-53. doi: 10.1111/bju.13160. Epub 2015 Jun 13.
Source | Full text | Similar articles

LOCAL TREATMENT

.

Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI.
Local Therapy Improves Survival in Metastatic Prostate Cancer.
Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30231-2. doi: 10.1016/j.eururo.2017.03.020. [Epub ahead of print]
Source | Full text | Similar articles

LOCAL TREATMENT OF THE PRIMARY TUMOR SITE

.

Moschini M, Soria F, Briganti A, Shariat SF.
The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients.
Prostate Cancer Prostatic Dis. 2016 Oct 25. doi: 10.1038/pcan.2016.52. [Epub ahead of print]
Source | Full text | Similar articles

PREDICTORS OF EARLY ANDROGEN DEPRIVATION TREATMENT FAILURE

.

Varenhorst E, Klaff R, Berglund A, Hedlund PO, Sandblom G; Scandinavian Prostate Cancer Group (SPCG) Trial No. 5.
Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.
Cancer Med. 2016 Jan 14. doi: 10.1002/cam4.594. [Epub ahead of print]
Source | Full text | Similar articles

TIME TO CASTRATION-RESISTANT PROSTATE CANCER

.

Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi JI, Ohta JI, Takebayashi S, Yokomizo Y, Hayashi N, Uemura H.
Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
Urol Int. 2017 Jun 14. doi: 10.1159/000477131. [Epub ahead of print]
Source | Full text | Similar articles

TIME FROM DEFINITIVE THERAPY TO ONSET OF METASTATIC DISEASE

.

Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N.
Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.
Urol Oncol. 2019 Feb 13. pii: S1078-1439(19)30050-X. doi: 10.1016/j.urolonc.2019.01.029. [Epub ahead of print]
Source | Full text | Similar articles